Associated Papers
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer.
Shen M et al.
Frontiers in Oncology, 2021
MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.
Pesenti C et al.
Endocrine, 2018
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Saida K et al.
Oncotarget, 2018
29682203 (PubMed )
Supplement: oncotarget-09-17043-s001.pdf
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Stjernström A et al.
Cancer Medicine, 2014
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT et al.
Archives of Pathology & Laboratory Medicine, 2012
Ampullary carcinoma-A genetic perspective.
Jayaramayya K et al.
Mutation Research. Reviews in Mutation Research, 0
Select a paper to view details